Genzyme General Acquires Lisfarma

Acquisition Will Accelerate Launch of Renagel(R) in Brazil



Apr 02, 2001, 01:00 ET from Genzyme General

    CAMBRIDGE, Mass., April 2 /PRNewswire/ -- Genzyme General (Nasdaq: GENZ),
 a division of Genzyme Corp., announced today that it has acquired Lisfarma
 Importacao, Exportacao e Comercio Ltda., a privately held pharmaceutical and
 medical company based in Sao Paolo, Brazil.  With the acquisition, Genzyme has
 obtained all of the government licenses granted to Lisfarma that are necessary
 to register, import, warehouse and distribute medical products in Brazil.
     In the near term, the transaction will allow Genzyme to seek registration
 of Renagel(R) (sevelamer hydrochloride) approximately two years sooner than
 would have been possible had Genzyme been required to obtain the licenses on
 its own.  It will also allow Genzyme to maintain exclusive control over
 Renagel and other products it introduces in Brazil.  Currently, Genzyme sells
 its products in Brazil either through distributors or on a named-patient
 basis.
     Renagel, a phosphate binder for patients with end-stage renal disease on
 dialysis, is Genzyme General's fastest growing product.  The Brazilian market
 is the largest potential market for Renagel outside of the United States,
 Europe, and Japan, with approximately 45,000 patients and a dialysis
 population that is growing at a rate of 12 percent per year.   Genzyme will
 apply for registration and reimbursement authorization for Renagel
 immediately, and expects to launch the product within 6-12 months.  Genzyme
 has begun building a 10-20 person dedicated Renagel sales and marketing
 organization in Brazil.
     "This is a strategic acquisition that will significantly accelerate the
 launch of Renagel in a large and rapidly growing market," said Henri A.
 Termeer, chairman and chief executive officer of Genzyme Corp.  "It also will
 allow us to introduce new products in Brazil more rapidly and expand our
 portfolio by distributing products developed by other biopharmaceutical
 companies.  The acquisition enhances the well-developed commercial
 infrastructure that is enabling us to sell our products throughout the world."
     Genzyme General develops and markets therapeutic products and diagnostic
 products and services.  Genzyme General has four therapeutic products on the
 market and a strong pipeline of therapeutic products in development focused
 primarily on the treatment of genetic diseases and other chronic, debilitating
 disorders with well-defined patient populations. Genzyme General is a division
 of the biotechnology company Genzyme Corporation.
     This press release contains forward-looking statements based on
 management's current expectations, including without limitation statements
 concerning: the impact of the acquisition on the time required to seek
 registration of and obtain necessary regulatory approvals for Renagel in
 Brazil and on Genzyme's ability to maintain exclusive control over the
 products it introduces in Brazil; the potential receipt of marketing approval
 for Renagel and other products in Brazil; estimates concerning the market for
 Renagel; the expected timing of a regulatory submission for Renagel and of the
 potential launch of Renagel in Brazil; the estimated size of the Renagel sales
 and marketing organization that will be used in Brazil; the possible
 distribution by Genzyme of products developed by other biopharmaceuticals
 companies; and the expected impact of the acquisition on Genzyme's commercial
 infrastructure.  Actual results may materially differ due to numerous factors,
 including without limitation; the actual timing of content of submissions to
 and decisions by the regulatory authorities in Brazil concerning Renagel and
 other products; the accuracy of Genzyme's estimates concerning the markets for
 Renagel, including growth projections; the ability to obtain necessary pricing
 and reimbursement approvals for Renagel and other products in Brazil; the
 competitive environment for Renagel; the ability to successfully negotiate and
 maintain distribution agreements with other biopharmaceuticals companies;
 Genzyme's ability to attract and retain qualified and experienced sales and
 marketing personnel in Brazil; Genzyme's ability to produce sufficient
 quantities of products for commercialization activities; Genzyme's ability to
 successfully retool and expand manufacturing systems related to Renagel; and
 the risks and uncertainties described in reports filed by Genzyme Corporation
 with the Securities and Exchange Commission under the Securities Exchange Act
 of 1934, as amended, including without limitation Exhibit 99.2 to Genzyme's
 1999 Annual Report on Form 10-K, as amended.  Genzyme General Division common
 stock is a series of common stock of Genzyme Corporation.  Therefore, holders
 of Genzyme General Division common stock are subject to all of the risks and
 uncertainties described in the aforementioned reports.
     Genzyme(R) is a registered trademark of Genzyme Corporation.  Renagel(R)
 is a registered trademark of GelTex Pharmaceuticals, Inc.  All rights
 reserved.
     Genzyme's releases are available on the World Wide Web at
 http://www.genzyme.com.  They are also available from Genzyme's fax-on-demand
 service at 1-800-436-1443 within the United States or 1-201-521-1080 outside
 the United States.
 
 

SOURCE Genzyme General
    CAMBRIDGE, Mass., April 2 /PRNewswire/ -- Genzyme General (Nasdaq: GENZ),
 a division of Genzyme Corp., announced today that it has acquired Lisfarma
 Importacao, Exportacao e Comercio Ltda., a privately held pharmaceutical and
 medical company based in Sao Paolo, Brazil.  With the acquisition, Genzyme has
 obtained all of the government licenses granted to Lisfarma that are necessary
 to register, import, warehouse and distribute medical products in Brazil.
     In the near term, the transaction will allow Genzyme to seek registration
 of Renagel(R) (sevelamer hydrochloride) approximately two years sooner than
 would have been possible had Genzyme been required to obtain the licenses on
 its own.  It will also allow Genzyme to maintain exclusive control over
 Renagel and other products it introduces in Brazil.  Currently, Genzyme sells
 its products in Brazil either through distributors or on a named-patient
 basis.
     Renagel, a phosphate binder for patients with end-stage renal disease on
 dialysis, is Genzyme General's fastest growing product.  The Brazilian market
 is the largest potential market for Renagel outside of the United States,
 Europe, and Japan, with approximately 45,000 patients and a dialysis
 population that is growing at a rate of 12 percent per year.   Genzyme will
 apply for registration and reimbursement authorization for Renagel
 immediately, and expects to launch the product within 6-12 months.  Genzyme
 has begun building a 10-20 person dedicated Renagel sales and marketing
 organization in Brazil.
     "This is a strategic acquisition that will significantly accelerate the
 launch of Renagel in a large and rapidly growing market," said Henri A.
 Termeer, chairman and chief executive officer of Genzyme Corp.  "It also will
 allow us to introduce new products in Brazil more rapidly and expand our
 portfolio by distributing products developed by other biopharmaceutical
 companies.  The acquisition enhances the well-developed commercial
 infrastructure that is enabling us to sell our products throughout the world."
     Genzyme General develops and markets therapeutic products and diagnostic
 products and services.  Genzyme General has four therapeutic products on the
 market and a strong pipeline of therapeutic products in development focused
 primarily on the treatment of genetic diseases and other chronic, debilitating
 disorders with well-defined patient populations. Genzyme General is a division
 of the biotechnology company Genzyme Corporation.
     This press release contains forward-looking statements based on
 management's current expectations, including without limitation statements
 concerning: the impact of the acquisition on the time required to seek
 registration of and obtain necessary regulatory approvals for Renagel in
 Brazil and on Genzyme's ability to maintain exclusive control over the
 products it introduces in Brazil; the potential receipt of marketing approval
 for Renagel and other products in Brazil; estimates concerning the market for
 Renagel; the expected timing of a regulatory submission for Renagel and of the
 potential launch of Renagel in Brazil; the estimated size of the Renagel sales
 and marketing organization that will be used in Brazil; the possible
 distribution by Genzyme of products developed by other biopharmaceuticals
 companies; and the expected impact of the acquisition on Genzyme's commercial
 infrastructure.  Actual results may materially differ due to numerous factors,
 including without limitation; the actual timing of content of submissions to
 and decisions by the regulatory authorities in Brazil concerning Renagel and
 other products; the accuracy of Genzyme's estimates concerning the markets for
 Renagel, including growth projections; the ability to obtain necessary pricing
 and reimbursement approvals for Renagel and other products in Brazil; the
 competitive environment for Renagel; the ability to successfully negotiate and
 maintain distribution agreements with other biopharmaceuticals companies;
 Genzyme's ability to attract and retain qualified and experienced sales and
 marketing personnel in Brazil; Genzyme's ability to produce sufficient
 quantities of products for commercialization activities; Genzyme's ability to
 successfully retool and expand manufacturing systems related to Renagel; and
 the risks and uncertainties described in reports filed by Genzyme Corporation
 with the Securities and Exchange Commission under the Securities Exchange Act
 of 1934, as amended, including without limitation Exhibit 99.2 to Genzyme's
 1999 Annual Report on Form 10-K, as amended.  Genzyme General Division common
 stock is a series of common stock of Genzyme Corporation.  Therefore, holders
 of Genzyme General Division common stock are subject to all of the risks and
 uncertainties described in the aforementioned reports.
     Genzyme(R) is a registered trademark of Genzyme Corporation.  Renagel(R)
 is a registered trademark of GelTex Pharmaceuticals, Inc.  All rights
 reserved.
     Genzyme's releases are available on the World Wide Web at
 http://www.genzyme.com.  They are also available from Genzyme's fax-on-demand
 service at 1-800-436-1443 within the United States or 1-201-521-1080 outside
 the United States.
 
 SOURCE  Genzyme General